Rexahn Pharmaceuticals to Present at the 5th NCI Pancreatic Cancer Symposium
September 18 2018 - 8:00AM
Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical-stage
biopharmaceutical company developing innovative, targeted
therapeutics for the treatment of cancer, will present preliminary
safety and efficacy data from the ongoing Phase 2a clinical trial
of RX-3117 in combination with Abraxane® in patients newly
diagnosed with metastatic pancreatic cancer at the 5th NCI
Pancreatic Cancer Symposium to be held October 2-3, 2018 at the
National Institutes of Health in Bethesda, Maryland. The conference
is being organized by the National Cancer Institute’s (NCI)
Pancreatic Cancer Interest Group and The University Medical Center,
Göttingen, Germany. The poster presentation is as follows:
Title: RX-3117, A Novel, Oral
Nucleoside Analog, in Combination with Nab-Paclitaxel (nab-pac) in
First-line Metastatic Pancreatic Cancer (met-PC): Safety,
Tolerability and Preliminary Responses
Session Date and Time: Tuesday, October 2,
2018; 2:35–3:20 p.m. EDT
Authors: Hani M. Babiker, Peter J. Schlegel,
Allyson J. Ocean, and Rexahn Pharmaceuticals.
A copy of the poster being presented will be available
on the Company's website at
https://rexahn.com/cms/media-center/publication/posters/ beginning
at 8:00 AM Eastern Time on Tuesday, October 2, 2018.
About RX-3117RX-3117 is a novel,
investigational, oral, small molecule nucleoside compound.
Once intracellularly activated (phosphorylated) by UCK2, it is
incorporated into the DNA or RNA of cells and inhibits both DNA and
RNA synthesis, which induces apoptotic cell death of tumor
cells. Because UCK2 is overexpressed in multiple human
tumors, but has a very limited presence in normal tissues, RX-3117
offers the potential for a targeted anti-cancer therapy with an
improved efficacy and safety profile. RX-3117 is currently
being studied in a Phase 2a clinical trial in in combination with
Abraxane® (nab-paclitaxel) in first line metastatic pancreatic
patients and a Phase 2a clinical trial in patients with advanced or
metastatic bladder cancer. It has received Orphan Drug designation
for the treatment of pancreatic cancer. Additional information on
RX-3117 can be found at:
https://rexahn.com/cms/portfolio/rx-3117/.
About Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals Inc. (NYSE American:RNN) is a clinical
stage biopharmaceutical company dedicated to developing novel,
targeted therapeutics for the treatment of cancer. The
company's mission is to improve the lives of cancer patients by
developing next-generation cancer therapies that are designed to
maximize efficacy while minimizing the toxicity and side effects
traditionally associated with cancer treatment. Rexahn's product
candidates work by targeting and neutralizing specific proteins
believed to be involved in the complex biological cascade that
leads to cancer cell growth. Preclinical studies show that certain
of Rexahn's product candidates may be effective against multiple
types of cancer, including drug resistant cancers, and
difficult-to-treat cancers, and others may augment the
effectiveness of current FDA-approved cancer treatments. The
company has two oncology product candidates, RX-3117 and RX-5902,
in Phase 2 clinical development and additional compounds in
preclinical development including RX-0201. For more information
about the Company and its oncology programs, please
visit www.rexahn.com.
Safe Harbor
To the extent any statements made in this press release deal
with information that is not historical, these are forward-looking
statements under the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to, statements
about Rexahn’s plans, objectives, expectations and intentions with
respect to cash flow requirements, future operations and products,
enrollments in clinical trials, the path of clinical trials and
development activities, and other statements identified by words
such as “will,” “potential,” ““could,”“ “can,” “believe,”
“intends,” “continue,” “plans,” “expects,” “anticipates,”
“estimates,” “may,” other words of similar meaning or the use of
future dates. Forward-looking statements by their nature address
matters that are, to different degrees, uncertain. Uncertainties
and risks may cause Rexahn’s actual results to be materially
different than those expressed in or implied by Rexahn’s
forward-looking statements. For Rexahn, particular uncertainties
and risks include, among others, understandings and beliefs
regarding the role of certain biological mechanisms and processes
in cancer; drug candidates being in early stages of development,
including clinical development; the ability to initially develop
drug candidates for orphan indications to reduce the time-to-market
and take advantage of certain incentives provided by the U.S. Food
and Drug Administration; the ability to transition from our initial
focus on developing drug candidates for orphan indications to
candidates for more highly prevalent indications; and the expecting
timing of results from our clinical trials. More detailed
information on these and additional factors that could affect
Rexahn’s actual results are described in Rexahn’s filings with the
Securities and Exchange Commission, including its most recent
annual report on Form 10-K and subsequent quarterly reports on Form
10-Q. All forward-looking statements in this news release speak
only as of the date of this news release. Rexahn undertakes no
obligation to update or revise any forward-looking statement,
whether as a result of new information, future events or
otherwise.
Media Contact:DGI CommSusan Forman or Laura
Radocaj
+1-212-825-3210sforman@dgicomm.comlradocaj@dgicomm.com
Investor contact:ir@rexahn.com
Rexahn Pharmaceuticals, Inc. (AMEX:RNN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rexahn Pharmaceuticals, Inc. (AMEX:RNN)
Historical Stock Chart
From Apr 2023 to Apr 2024